Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Yinge X. QIAN |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder / Jeanne M. MADDEN in Journal of Autism and Developmental Disorders, 47-1 (January 2017)
[article]
Titre : Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Jeanne M. MADDEN, Auteur ; Matthew D. LAKOMA, Auteur ; Frances L. LYNCH, Auteur ; Donna RUSINAK, Auteur ; Ashli A. OWEN-SMITH, Auteur ; Karen J. COLEMAN, Auteur ; Virginia P. QUINN, Auteur ; Vincent M. YAU, Auteur ; Yinge X. QIAN, Auteur ; Lisa A. CROEN, Auteur Article en page(s) : p.144-154 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Medications Antipsychotics Comorbidities Epidemiological studies Index. décimale : PER Périodiques Résumé : This study examined psychotropic medication use among 7901 children aged 1–17 with autism spectrum disorder (ASD) in five health systems, comparing to matched cohorts with no ASD. Nearly half (48.5?%) of children with ASD received psychotropics in the year observed; the most common classes were stimulants, alpha-agonists, or atomoxetine (30.2?%), antipsychotics (20.5?%), and antidepressants (17.8?%). Psychotropic treatment was far more prevalent among children with ASD, as compared to children with no ASD (7.7?% overall), even within strata defined by the presence or absence of other psychiatric diagnoses. The widespread use of psychotropics we observed, particularly given weak evidence supporting the effectiveness of these medications for most children with ASD, highlights challenges in ASD treatment and the need for greater investment in its evaluation. En ligne : http://dx.doi.org/10.1007/s10803-016-2946-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=298
in Journal of Autism and Developmental Disorders > 47-1 (January 2017) . - p.144-154[article] Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Jeanne M. MADDEN, Auteur ; Matthew D. LAKOMA, Auteur ; Frances L. LYNCH, Auteur ; Donna RUSINAK, Auteur ; Ashli A. OWEN-SMITH, Auteur ; Karen J. COLEMAN, Auteur ; Virginia P. QUINN, Auteur ; Vincent M. YAU, Auteur ; Yinge X. QIAN, Auteur ; Lisa A. CROEN, Auteur . - p.144-154.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 47-1 (January 2017) . - p.144-154
Mots-clés : Autism spectrum disorder Medications Antipsychotics Comorbidities Epidemiological studies Index. décimale : PER Périodiques Résumé : This study examined psychotropic medication use among 7901 children aged 1–17 with autism spectrum disorder (ASD) in five health systems, comparing to matched cohorts with no ASD. Nearly half (48.5?%) of children with ASD received psychotropics in the year observed; the most common classes were stimulants, alpha-agonists, or atomoxetine (30.2?%), antipsychotics (20.5?%), and antidepressants (17.8?%). Psychotropic treatment was far more prevalent among children with ASD, as compared to children with no ASD (7.7?% overall), even within strata defined by the presence or absence of other psychiatric diagnoses. The widespread use of psychotropics we observed, particularly given weak evidence supporting the effectiveness of these medications for most children with ASD, highlights challenges in ASD treatment and the need for greater investment in its evaluation. En ligne : http://dx.doi.org/10.1007/s10803-016-2946-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=298